Journal
NEURO-ONCOLOGY
Volume 22, Issue 9, Pages 1249-1261Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noaa116
Keywords
brain cancer; failure analysis; glioma; glioblastoma; immunology; immunotherapy
Categories
Funding
- NINDS [K08 NS099484]
- NATIONAL CANCER INSTITUTE [ZIABC011640, ZIABC011647, ZIABC011643, ZIDBC011642, ZIABC011714] Funding Source: NIH RePORTER
Ask authors/readers for more resources
In oncology, immunotherapy is a broad term encompassing multiple means of utilizing the patient's immune system to combat malignancy. Prominent among these are immune checkpoint inhibitors, cellular therapies including chimeric antigen receptor T-cell therapy, vaccines, and oncolytic viruses. Immunotherapy for glioblastoma (GBM) has had mixed results in early trials. in this context, the past, present, and future of immune oncology for the treatment of GBM was discussed by clinical, research, and thought leaders as well as patient advocates at the first annual Remission Summit in 2019. The goal was to use current knowledge (published and unpublished) to identify possible causes of treatment failures and the best strategies to advance immunotherapy as a treatment modality for patients with GBM. The discussion focuses on past failures, current limitations, failure analyses, and proposed best practices moving forward.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available